Research and Development Investment: Eli Lilly and Company vs Bausch Health Companies Inc.

Eli Lilly's R&D investment dwarfs Bausch Health's over a decade.

__timestampBausch Health Companies Inc.Eli Lilly and Company
Wednesday, January 1, 20142460000004733600000
Thursday, January 1, 20155828000004796400000
Friday, January 1, 20164550000005243900000
Sunday, January 1, 20173660000005281800000
Monday, January 1, 20184140000005051200000
Tuesday, January 1, 20194710000005595000000
Wednesday, January 1, 20204520000006085700000
Friday, January 1, 20214650000007025900000
Saturday, January 1, 20225290000007190800000
Sunday, January 1, 20236040000009313400000
Monday, January 1, 202414271000000
Loading chart...

Data in motion

A Decade of R&D Investment: Eli Lilly vs. Bausch Health

In the ever-evolving pharmaceutical industry, research and development (R&D) investment is crucial for innovation and growth. Over the past decade, Eli Lilly and Company has consistently outpaced Bausch Health Companies Inc. in R&D spending. From 2014 to 2023, Eli Lilly's R&D expenses surged by nearly 97%, reaching a peak in 2023. In contrast, Bausch Health's investment grew by approximately 146%, yet remained significantly lower in absolute terms.

Key Insights

Eli Lilly's commitment to R&D is evident, with its 2023 investment being nearly 15 times that of Bausch Health. This disparity highlights Eli Lilly's strategic focus on innovation, potentially leading to a stronger pipeline of new drugs. As the pharmaceutical landscape becomes increasingly competitive, such investments are likely to play a pivotal role in shaping the future of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025